Redx Pharma plc Directorate Change (8983N)
August 14 2017 - 4:05AM
UK Regulatory
TIDMREDX
RNS Number : 8983N
Redx Pharma plc
14 August 2017
14 August 2017
AIM: REDX
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
THE MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION
IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
REDX PHARMA PLC (in administration)
("Redx" or "the Company")
Redx announces the resignation of Non-Executive Director David
Lawrence
Redx (AIM: REDX), the drug discovery and development company
focused on cancer and immunology, announces that David Lawrence has
resigned from the Board with immediate effect.
David Lawrence said, "I have recently commenced an executive
role and it is important that I focus upon that. Now that it is
clear that Redx will likely exit administration, I feel that the
Company's future is on the way to be secured so I would like to
wish the Company and the Board my best wishes going forward"
Iain Ross, non-executive Chairman commented, "On behalf of the
Company I would like to thank David for his contribution to the
Company over the last 16 months and we wish him well in the
future"
For further information, please contact:
Redx Pharma Plc (in administration)
Contact for the Joint Administrators:
James Rossiter (Morgan Rossiter) +44 203 195 3240
Cantor Fitzgerald Europe (Nomad & Broker) +44 207 894 7000
Phil Davies/ Michael Reynolds
WG Partners (Joint Broker) +44 203 705 9317
Claes Spång/ Chris Lee/ David Wilson
About RXC004
Redx's Porcupine inhibitor RXC004 exhibits potent and selective
inhibition of the Wnt pathway in in vitro and in vivo models of Wnt
dependant cancer. Preliminary results indicate that RXC004 may also
enhance the efficacy of checkpoint inhibitors, such as anti-PD-1
antibodies.
About Redx Pharma Plc (in administration)
Company website: Redxpharma.com
Redx is focused on the discovery and development of proprietary,
small molecule therapeutics to address areas of high, unmet medical
need, principally in cancer, immunology and infection, providing a
pipeline of assets to larger and emerging companies. By improving
the characteristics of existing drug classes to create highly
differentiated, novel, best-in-class drugs, Redx has already
established a broad portfolio of proprietary drug programs.
Jason Baker and Miles Needham have been appointed as joint
administrators of Redx Pharma plc (in administration). The
Company's affairs, business and property are being managed by the
joint administrators.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOASFDSULFWSESA
(END) Dow Jones Newswires
August 14, 2017 05:05 ET (09:05 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024